Drugs / SOF/LDV
SOF/LDV
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT02786537 Comparator | Jun 2016 → Jun 2019 | chronic hepatitis C virus infection | University of Florida | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SOF/LDV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02786537 ↗ |
| Known as | Harvoni (sofosbuvir/ledipasvir) | “Harvoni® (sofosbuvir/ledipasvir)” NCT02786537 ↗ |
| Known as | sofosbuvir/ledipasvir | “SOF/LDV (sofosbuvir/ledipasvir)” NCT02786537 ↗ |
| Route | Oral | “tablet (400/90 mg) orally once daily” NCT02786537 ↗ |